ArticleJournal of nanobiotechnology2025
LNP-enclosed NamiRNA inhibits pancreatic cancer proliferation and migration via dual pathways.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MiRNAs in hyperglycemia-induced metabolic memory: established mechanisms and emerging nuclear activation concepts.Diabetology & metabolic syndrome · 2026Review
- The Multi-Target lncRNA-miRNA-mRNA TRIAD in Pancreatic Cancer Diagnosis and Therapy.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPancreatic cancer is a highly aggressive malignancy characterized by limited treatment options, poor prognosis, and high mortality rates. nuclear activating miRNA (NamiRNA) enhances gene expression by interacting with nuclear enhancers, offering a novel avenue for understanding gene regulation in cancer. This study explores the dual role of mir-200c in regulating tumor proliferation and migration in pancreatic cancer, with the aim of identifying potential therapeutic strategies.
resultsMir-200c significantly activated PTPN6 transcription via the NamiRNA-enhancer pathway, reducing tumor proliferation. Deletion of the enhancer sequence abolished the activation of PTPN6. Furthermore, mir-200c mediated the post-transcriptional repression of CDH17, impairing tumor migration. In vivo, LNP-enclosed mir-200c exhibited strong anti-tumor effects, further validating its therapeutic potential.
conclusionsMir-200c inhibits pancreatic cancer cell proliferation and migration through dual mechanisms: activation of PTPN6 transcription and repression of CDH17 expression. These findings suggest that mir-200c, particularly when delivered via LNP systems, may serve as a promising therapeutic strategy for pancreatic cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.